Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Journal of acquired immune deficiency syndromes (1999) - 1 May 2003

Margot Nicolas A, Isaacson Erica, McGowan Ian, Cheng Andrew, Miller Michael D

Abstract excerpt

OBJECTIVE: To study the potential development of genotypic and phenotypic resistance to tenofovir disoproxil fumarate (tenofovir DF) when used as a part of a 96-week HIV-1 treatment regimen for antiretroviral treatment-experienced HIV-infected patients. DESIGN AND METHODS: Clinical trial GS-98-902 was a placebo-controlled, 48-week phase 2 study of three doses of tenofovir DF when added to stable antiretroviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Organophosphonates

Share to Organophosphorus Compounds

Share to Tenofovir

Source

Identifiers

PMID: 12792350
DOI: 10.1097/00126334-200305010-00003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.PMID 12792350Read ↗

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.Semantic proximity Read ↗

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Semantic proximity Read ↗

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.Semantic proximity Read ↗

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.Semantic proximity Read ↗

Tenofovir disoproxil fumarate.Semantic proximity Read ↗

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

Tenofovir disoproxil fumarate.Semantic proximity Read ↗

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.Semantic proximity Read ↗

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Semantic proximity Read ↗

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.Semantic proximity Read ↗

Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.